| CAS ID: | 366789-02-8 |
| Molecular Formula: | C19H18ClN3O5S |
| Molecular Weight: | 435.9 g/mol |
| Monoisotopic Mass: | 435.0656 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | RIVAROXABAN | XARELTO | BAY 59-7939 |
| Analysis: | Drug repositioning mechanism analysis |
Reference Record 1
| PubMed ID | 26370374 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro | Fibrosis Disease | Cardiac fibrosis |
| Process I | attenue inflammation | ||
| Process II | fibroblasts activation,fibroblasts proliferation,fibroblasts migration | ||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT02643212 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Recruiting |
| First Received | December 31, 2015 | Last Verified | April 25, 2018 |
| Sponsor | David Garcia Cinca | ||
| PubChem: | 9875401 |
| ChEMBL: | CHEMBL198362 |